MedTrace Logo

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

NCT01127451 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2022-04-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether participants with Stage IIIC and Stage IV Melanoma experience benefit when treated with Denileukin diftitox in two different dosing schedules.

Conditions

  • Stage IIIC Melanoma
  • Stage IV Melanoma

Interventions

DRUG

Denileukin diftitox

Denileukin diftitox intravenous infusion over 30-60 minutes.

Sponsors & Collaborators

  • PharmaBio Development Inc.

    collaborator INDUSTRY

  • Eisai Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-22
Primary Completion
2015-04-07
Completion
2015-04-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01127451 on ClinicalTrials.gov